Pregled bibliografske jedinice broj: 587138
Decreased soluble dipeptidyl peptidase IV activity as a potential serum biomarker for COPD
Decreased soluble dipeptidyl peptidase IV activity as a potential serum biomarker for COPD // Clinical biochemistry, 45 (2012), 15; 1245-1250 doi:10.1016/j.clinbiochem.2012.04.023 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 587138 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Decreased soluble dipeptidyl peptidase IV activity as a potential serum biomarker for COPD
Autori
Somborac Bačura, Anita ; Buljević, Sunčica ; Rumora, Lada ; Čulić, Ognjen ; Detel, Dijana ; Pancirov, Dolores ; Popović-Grle, Sanja ; Varljen, Jadranka ; Čepelak, Ivana ; Žanić Grubišić, Tihana
Izvornik
Clinical biochemistry (0009-9120) 45
(2012), 15;
1245-1250
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
soluble dipeptidyl peptidase IV ; chronic obstructive pulmonary disease ; biomarker ; C-reactive protein ; GOLD stage
Sažetak
Objectives: The objective of this study was to measure soluble dipeptidyl peptidase IV (sDPPIV) activity in sera of patients with stable chronic obstructive pulmonary disease (COPD) in comparison to healthy controls. The main goal was to assess changes in the enzyme activity in relation to severity of the disease, age and smoking history and to evaluate diagnostic accuracy for prediction of COPD by level of serum sDPPIV activity. Design and methods: The study included 106 patients with stable COPD (GOLD II–GOLD IV stages) and 38 healthy controls. Serum sDPPIV activity as well as some inflammatory markers (CRP, total and differential leukocyte counts) was measured. Multivariate logistic regression models were applied to analyze association of sDPPIV activity and inflammatory markers in risk estimation for COPD development. Results: sDPPIV activity in COPD patients was significantly reduced when compared to healthy controls. Decrease was observed already in GOLD II stage. Age and smoking history did not influence sDPPIV activity. Very good diagnostic accuracy (AUC = 0.833 ; sensitivity and specificity of 85.7% and 78.9%, respectively) for GOLD II and good diagnostic accuracy (AUC = 0.801 ; sensitivity and specificity of 65.1% and 86.8%, respectively) for total cohort of COPD patients were found. The multivariate logistic regression model showed that the use of sDPPIV in combination with CRP and lymphocyte proportion improved diagnostic strength and gave an AUC of 0.933. Conclusions: sDPPIV activity is decreased in COPD patients as early as in GOLD II stage. Very good diagnostic accuracy of sDPPIV activity suggests it as a candidate biomarker for early diagnosis of COPD.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Farmacija
POVEZANOST RADA
Projekti:
006-0061245-0977 - Molekularni mehanizmi patogeneze kronične opstrukcijske bolesti pluća (Žanić-Grubišić, Tihana, MZOS ) ( CroRIS)
062-0061245-0213 - Uloga dipeptidil-peptidaze IV (CD26/DPP IV) u kroničnim bolestima (Varljen, Jadranka, MZOS ) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Medicinski fakultet, Rijeka
Profili:
Dijana Detel
(autor)
Lada Rumora
(autor)
Sanja Popović-Grle
(autor)
Anita Somborac Bačura
(autor)
Sunčica Buljević
(autor)
Ivana Čepelak
(autor)
Tihana Žanić-Grubišić
(autor)
Jadranka Varljen
(autor)
Ognjen Čulić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE